Dean F Bajorin Selected Research

Platinum

1/2023	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
10/2022	Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
5/2021	Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].
12/2020	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
12/2020	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
10/2020	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
10/2019	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
10/2018	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
1/2018	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
7/2017	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dean F Bajorin Research Topics

Disease

86	Neoplasms (Cancer) 04/2024 - 01/2002
58	Carcinoma (Carcinomatosis) 01/2024 - 09/2006
39	Urinary Bladder Neoplasms (Bladder Cancer) 05/2024 - 03/2002
16	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 09/2023 - 11/2002
11	Neoplasm Metastasis (Metastasis) 12/2020 - 01/2007
7	Teratoma (Teratoid Tumor) 10/2019 - 12/2003
7	Testicular Neoplasms (Testicular Cancer) 04/2010 - 12/2003
5	Non-Muscle Invasive Bladder Neoplasms 05/2024 - 04/2016
4	Nonseminomatous germ cell tumor 08/2018 - 12/2007
4	Transitional Cell Carcinoma 03/2011 - 12/2003
3	Carcinoma in Situ 05/2024 - 04/2017
3	Fatigue 10/2022 - 01/2018
3	Fibrosis (Cirrhosis) 01/2019 - 01/2002
3	Carcinogenesis 12/2017 - 12/2010
2	Hearing Loss (Hearing Impairment) 09/2023 - 06/2011
2	Small Cell Carcinoma 10/2022 - 01/2021
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2008
2	Pathologic Complete Response 01/2021 - 04/2010
2	Disease Progression 01/2021 - 01/2002
2	Margins of Excision 10/2020 - 12/2019
2	Embryonal Carcinoma 01/2017 - 08/2005
2	Hypoxia (Hypoxemia) 08/2011 - 03/2011
2	Breast Neoplasms (Breast Cancer) 11/2009 - 01/2008
2	Leukemia 10/2009 - 12/2003
2	Seminoma 01/2002 - 01/2002
1	Rare Diseases (Rare Disease) 01/2024
1	Ototoxicity 09/2023
1	Diarrhea 01/2023
1	Human Influenza (Influenza) 01/2022
1	Urachal adenocarcinoma 01/2022
1	Pneumonia (Pneumonitis) 01/2021

Drug/Important Bio-Agent (IBA)

32	Cisplatin (Platino)FDA LinkGeneric 04/2024 - 01/2002
20	PlatinumIBA 01/2023 - 01/2002
13	Gemcitabine FDA Link 04/2024 - 02/2007
12	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2002
11	Immune Checkpoint InhibitorsIBA 11/2022 - 10/2018
9	NivolumabIBA 02/2023 - 10/2018
8	pembrolizumabIBA 05/2024 - 01/2017
8	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 09/2014
7	Carboplatin (JM8)FDA LinkGeneric 09/2023 - 02/2007
7	B7-H1 AntigenIBA 01/2023 - 01/2017
7	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 01/2002
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 02/2007
6	atezolizumabIBA 01/2022 - 01/2017
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 01/2002
5	AntibodiesIBA 01/2019 - 12/2003
5	Ifosfamide FDA LinkGeneric 01/2016 - 02/2007
4	ChromatinIBA 12/2022 - 02/2015
4	Hemoglobins (Hemoglobin)IBA 01/2018 - 04/2013
4	CreatinineIBA 01/2018 - 02/2007
4	Everolimus FDA Link 04/2017 - 10/2012
4	TOR Serine-Threonine KinasesIBA 08/2013 - 03/2011
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2008
3	durvalumabIBA 01/2023 - 12/2020
3	RNA (Ribonucleic Acid)IBA 04/2018 - 06/2006
3	AlbuminsIBA 01/2018 - 04/2013
3	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2009 - 02/2007
3	VaccinesIBA 11/2008 - 12/2003
3	AntigensIBA 03/2007 - 12/2003
2	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 05/2021 - 12/2020
2	tremelimumabIBA 01/2021 - 12/2020
2	IpilimumabIBA 01/2021 - 12/2020
2	Phosphotransferases (Kinase)IBA 10/2020 - 02/2015
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2020 - 09/2010
2	ElementsIBA 10/2019 - 04/2018
2	Bevacizumab (Avastin)FDA Link 03/2016 - 02/2013
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016 - 10/2015
2	Pemetrexed (MTA)FDA Link 05/2015 - 06/2007
2	Sunitinib (Sutent)FDA Link 08/2011 - 03/2010
2	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 04/2010 - 04/2010
1	erdafitinibIBA 11/2023
1	Amylases FDA Link 01/2023
1	Lipase (Acid Lipase)FDA Link 01/2023
1	Genetic Markers (Genetic Marker)IBA 01/2023
1	palladium-bacteriopheophorbideIBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023
1	Photosensitizing Agents (Photosensitizers)IBA 01/2023
1	olaparibIBA 01/2023
1	padeliporfinIBA 01/2023
1	Circulating Tumor DNAIBA 12/2022
1	Transcription Factors (Transcription Factor)IBA 11/2022
1	Blocking AntibodiesIBA 01/2021

Therapy/Procedure

61	Drug Therapy (Chemotherapy) 04/2024 - 01/2002
41	Therapeutics 04/2024 - 12/2003
24	Cystectomy 05/2024 - 03/2002
18	Neoadjuvant Therapy 04/2024 - 02/2007
18	Lymph Node Excision (Lymph Node Dissection) 01/2024 - 03/2002
15	Immunotherapy 11/2022 - 04/2016
7	Salvage Therapy 01/2024 - 04/2010
6	Adjuvant Chemotherapy 10/2022 - 08/2005
5	Combination Drug Therapy (Combination Chemotherapy) 12/2019 - 06/2011
3	Nephroureterectomy 01/2024 - 01/2016
3	Aftercare (After-Treatment) 01/2018 - 02/2015
2	Induction Chemotherapy 02/2015 - 02/2008
2	Radiotherapy 01/2014 - 01/2008
2	Orchiectomy (Orchidectomy) 11/2011 - 04/2010
1	Hearing Aids (Hearing Aid) 09/2023
1	Intravenous Infusions 01/2023
1	Photochemotherapy (Photodynamic Therapy) 01/2023
1	Chemoradiotherapy 10/2022